CoChat

Identification of Candidate Biomarkers of Therapeutic Response to Docetaxel by Proteomic Profiling

Zhao, Liangli, Lee, Brian Y., Brown, David A., Molloy, Mark P., Marx, Gavin M., Pavlakis, Nick, Boyer, Michael J., Stockler, Martin R., Kaplan, Warren, Breit, Samuel N., Sutherland, Robert L., Henshall, Susan M., Horvath, Lisa G. · 2009 · Cancer Research
Cited by 104

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Docetaxel chemotherapy improves symptoms and survival in men with metastatic hormone-refractory prostate cancer (HRPC). However, ∼50% of patients do not respond to Docetaxel and are exposed to significant toxicity without direct benefit. This study aimed to identify novel therapeutic targets and predictive biomarkers of Docetaxel resistance in HRPC. We used iTRAQ-mass spectrometry analysis to identify proteins associated with the development of Docetaxel resistance using Docetaxel-sensitive PC3 cells and Docetaxel-resistant PC3-Rx cells developed by Docetaxel dose escalation. Functional validation experiments were performed using recombinant protein treatment and siRNA knockdown experiments. Serum/plasma levels of the targets in patient samples were measured by ELISA. The IC50 for Docetaxel in the PC3-Rx cells was 13-fold greater than the parent PC-3 cell line (P = 0.004). Protein profiling identified MIC-1 and AGR2 as respectively up-regulated and down-regulated in Docetaxel-resistant cells. PC-3 cells treated with recombinant MIC-1 also became resistant to Docetaxel (P = 0.03). Conversely, treating PC3-Rx cells with MIC-1 siRNA restored sensitivity to Docetaxel (P = 0.02). Knockdown of AGR2 expression in PC3 cells resulted in Docetaxel resistance (P = 0.007). Furthermore, increased serum/plasma levels of MIC-1 after cycle one of chemotherapy were associated with progression of the cancer (P = 0.006) and shorter survival after treatment (P = 0.002). These results suggest that both AGR2 and MIC-1 play a role in Docetaxel resistance in HRPC. In addition, an increase in serum/plasma MIC-1 level after cycle one of Docetaxel may be an indication to abandon further treatment. Further investigation of MIC-1 as a biomarker and therapeutic target for Docetaxel resistance in HRPC is warranted. [Cancer Res 2009;69(19):7696–7703]

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-08-4901

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 104

Metadata

Authors
Zhao, L., Lee, B. Y., Brown, D. A., Molloy, M. P., Marx, G. M., Pavlakis, N., Boyer, M. J., Stockler, M. R., Kaplan, W., Breit, S. N., Sutherland, R. L., Henshall, S. M., & Horvath, L. G.
Venue
Cancer Research
Published
2009-10-01
Volume
69
Issue
19
Pages
7696-7703
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2158732421
Cited by
104
References
4
FWCI
7.62
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Identification of Candidate Biomarkers of Therapeutic Response to Docetaxel by Proteomic Profiling. https://app.cochat.ai/papers/10.1158/0008-5472.can-08-4901
The paper
Zhao, L., Lee, B. Y., Brown, D. A., Molloy, M. P., Marx, G. M., Pavlakis, N., Boyer, M. J., Stockler, M. R., Kaplan, W., Breit, S. N., Sutherland, R. L., Henshall, S. M., & Horvath, L. G. (2009). Identification of Candidate Biomarkers of Therapeutic Response to Docetaxel by Proteomic Profiling. Cancer Research. https://doi.org/10.1158/0008-5472.can-08-4901

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.